دورية أكاديمية
أعرض في EDS

Three-week hypofractionated radiotherapy in early glottic cancer-a single institution retrospective study.

التفاصيل البيبلوغرافية
العنوان: Three-week hypofractionated radiotherapy in early glottic cancer-a single institution retrospective study.
المؤلفون: Sudha AS; Department of Radiation Oncology, Regional Cancer Centre, Thiruvananthapuram 695011, Kerala, India., Kumar RR; Department of Radiation Oncology, Regional Cancer Centre, Thiruvananthapuram 695011, Kerala, India., Anjanappa M; Department of Radiation Oncology, Regional Cancer Centre, Thiruvananthapuram 695011, Kerala, India., Kainickal CT; Department of Radiation Oncology, Regional Cancer Centre, Thiruvananthapuram 695011, Kerala, India., Mathew A; Department of Epidemiology & Biostatistics, Regional Cancer Centre, Thiruvananthapuram 695011, Kerala, India., Kunnambath R; Department of Radiation Oncology, Regional Cancer Centre, Thiruvananthapuram 695011, Kerala, India.
المصدر: Ecancermedicalscience [Ecancermedicalscience] 2022 May 04; Vol. 16, pp. 1381. Date of Electronic Publication: 2022 May 04 (Print Publication: 2022).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: ecancer Country of Publication: England NLM ID: 101392236 Publication Model: eCollection Cited Medium: Print ISSN: 1754-6605 (Print) Linking ISSN: 17546605 NLM ISO Abbreviation: Ecancermedicalscience Subsets: PubMed not MEDLINE
أسماء مطبوعة: Publication: Bristol, UK : ecancer
Original Publication: Bristol, UK : Cancer Intelligence
مستخلص: Background: Radiotherapy is a standard treatment option for early glottic carcinoma (stage I and II) with a fraction size of 2-2.2 Gy over 5-7 weeks. This study evaluates the outcome and prognostic factors of a 3-week hypofractionated treatment in early glottic malignancy.
Materials and Methods: The case records of 329 eligible patients with stage I and II glottic carcinoma recorded at the institution from 2003 to 2008 were retrospectively analysed. All patients were treated in a Cobalt-60 machine to a dose of 52.5 Gy in 15 fractions (3.5 Gy/fraction) over 3 weeks.
Results: Eighty-three percent had stage I disease. The local control rate at 5 years was 91.9%. On univariate analysis, stage I and II patients without subglottic extension had better local control. Disease extension to the subglottis fared poorly on multivariate analysis. After salvage treatment, the 5-year disease-free survival rate was 96.1% and the functional larynx preservation rate was 94.9% for stage I and 83.9% for stage II. The rate of severe complications was 2.1%.
Conclusion: Comparable results with low morbidity are achievable with a 3-week hypofractionation in early glottic cancers and it offers better patient convenience.
Highlights: In early glottic cancer, hypofractionated radiation provides excellent local control.Subglottic extension is a poor prognostic factor.5-year disease-free survival rate of 96.1%.5-year functional larynx preservation rate of 94.9%.Severe complication rate of 2.1%.
Competing Interests: None of the authors have any conflict of interest in the publication of this manuscript.
(© the authors; licensee ecancermedicalscience.)
References: Front Oncol. 2019 Sep 20;9:932. (PMID: 31616637)
Radiat Oncol. 2011 May 21;6:53. (PMID: 21600025)
Int J Radiat Oncol Biol Phys. 1992;23(2):457-67. (PMID: 1534082)
Br J Radiol. 1991 Mar;64(759):232-41. (PMID: 2021797)
Radiat Med. 1996 Nov-Dec;14(6):297-302. (PMID: 9132809)
Strahlenther Onkol. 2017 Dec;193(12):995-1004. (PMID: 28474090)
Radiat Oncol. 2015 Sep 23;10:203. (PMID: 26395876)
Am J Otolaryngol. 2001 Jan-Feb;22(1):43-54. (PMID: 11172214)
Clin Oncol (R Coll Radiol). 2012 Dec;24(10):e180-6. (PMID: 22862908)
Int J Radiat Oncol Biol Phys. 1988 Mar;14(3):451-4. (PMID: 3343152)
Radiology. 1992 Jan;182(1):273-5. (PMID: 1727295)
Int J Radiat Oncol Biol Phys. 1998 May 1;41(2):347-53. (PMID: 9607350)
Radiother Oncol. 1994 Apr;31(1):14-22. (PMID: 8041895)
Strahlenther Onkol. 2019 Sep;195(9):792-804. (PMID: 31214734)
Radiother Oncol. 2016 Feb;118(2):257-66. (PMID: 26897514)
Int J Radiat Oncol Biol Phys. 1997 Jul 15;38(5):1001-6. (PMID: 9276365)
Int J Radiat Oncol Biol Phys. 1997 Feb 1;37(3):587-91. (PMID: 9112457)
Int J Radiat Oncol Biol Phys. 2000 Oct 1;48(3):723-35. (PMID: 11020569)
Int J Radiat Oncol Biol Phys. 1990 Jun;18(6):1307-13. (PMID: 2370181)
Int J Radiat Oncol Biol Phys. 2007 Dec 1;69(5):1389-94. (PMID: 17869013)
Arch Otolaryngol Head Neck Surg. 1991 Mar;117(3):297-301. (PMID: 1998569)
Radiother Oncol. 2003 Aug;68(2):105-11. (PMID: 12972304)
Int J Radiat Oncol Biol Phys. 1996 Aug 1;36(1):181-7. (PMID: 8823274)
Radiother Oncol. 2014 Jan;110(1):98-103. (PMID: 24161568)
Int J Radiat Oncol Biol Phys. 1997 Aug 1;39(1):115-26. (PMID: 9300746)
Radiother Oncol. 1996 Sep;40(3):225-32. (PMID: 8940749)
Clin Otolaryngol Allied Sci. 1994 Apr;19(2):105-8. (PMID: 8026085)
Cancer. 2003 Aug 15;98(4):765-72. (PMID: 12910521)
Clin Transl Oncol. 2020 Jan;22(1):151-157. (PMID: 31152306)
Int J Radiat Oncol Biol Phys. 1996 Mar 1;34(4):823-31. (PMID: 8598359)
Ann Oncol. 2018 Apr 1;29(4):992-997. (PMID: 29401241)
Radiother Oncol. 1994 Feb;30(2):109-20. (PMID: 8184108)
Int J Radiat Oncol Biol Phys. 2003 Feb 1;55(2):322-8. (PMID: 12527044)
Head Neck. 2016 Dec;38(12):1832-1836. (PMID: 27299502)
Acta Oncol. 2004;43(3):284-9. (PMID: 15244253)
Laryngoscope. 2011 Jan;121(1):116-34. (PMID: 21120828)
Radiother Oncol. 2006 Feb;78(2):159-64. (PMID: 16360226)
Int J Radiat Oncol Biol Phys. 1993 Aug 1;26(5):767-72. (PMID: 8344844)
Int J Radiat Oncol Biol Phys. 1991 Jun;20(6):1215-8. (PMID: 1904409)
Radiat Oncol. 2017 Nov 14;12(1):178. (PMID: 29137654)
Int J Radiat Oncol Biol Phys. 1998 Sep 1;42(2):247-55. (PMID: 9788401)
Int J Radiat Oncol Biol Phys. 1979 Apr;5(4):477-82. (PMID: 457492)
Oral Oncol. 2019 Jun;93:8-14. (PMID: 31109700)
Int J Radiat Oncol Biol Phys. 1999 Mar 15;43(5):1009-13. (PMID: 10192348)
Int J Radiat Oncol Biol Phys. 1988 Dec;15(6):1267-73. (PMID: 3143690)
Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1378-86. (PMID: 16095847)
Cancer. 1982 Feb 15;49(4):655-8. (PMID: 7055780)
Int J Radiat Oncol Biol Phys. 1977 Jul-Aug;2(7-8):613-9. (PMID: 408306)
J Clin Oncol. 2001 Oct 15;19(20):4029-36. (PMID: 11600604)
Radiother Oncol. 1998 May;47(2):155-9. (PMID: 9683363)
Int J Radiat Oncol Biol Phys. 1979 Apr;5(4):473-6. (PMID: 457491)
Int J Radiat Oncol Biol Phys. 2010 Oct 1;78(2):461-6. (PMID: 20153124)
Med Phys. 1987 Jan-Feb;14(1):140-4. (PMID: 3104739)
Clin Oncol (R Coll Radiol). 2017 Jan;29(1):42-50. (PMID: 27815039)
Int J Radiat Oncol Biol Phys. 1990 Jan;18(1):119-23. (PMID: 2404917)
Int J Radiat Oncol Biol Phys. 2006 Jan 1;64(1):77-82. (PMID: 16169681)
فهرسة مساهمة: Keywords: glottic cancers; hypofractionation; radiotherapy
تواريخ الأحداث: Date Created: 20220803 Latest Revision: 20220805
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC9300409
DOI: 10.3332/ecancer.2022.1381
PMID: 35919227
قاعدة البيانات: MEDLINE
الوصف
تدمد:1754-6605
DOI:10.3332/ecancer.2022.1381